Auranofin: repurposing an old drug for a golden new age Roder, Christine and Thomson, Melanie J. 2015, Auranofin: repurposing an old drug for a golden new age, Drugs in R&D, vol. 15, no. 1, pp. 13-20, doi: 10.1007/s40268-015-0083-y. Attached Files Name Description MIMEType Size Downloads Title Auranofin: repurposing an old drug for a golden new age Author(s) Roder, Christine Thomson, Melanie J. Journal name Drugs in R&D Volume number 15 Issue number 1 Start page 13 End page 20 Total pages 8 Publisher Adis International Place of publication Auckland, N.Z Publication date 2015-03 ISSN 1179-6901 Summary Drug discovery, development and registration is an expensive and time-consuming process associated with a high failure rate [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Woodcock and Woosley (Annu Rev Med 59:1-12, 2008)]. Drug 'repurposing' is the identification of new therapeutic purposes for already approved drugs and is more affordable and achievable than novel drug discovery [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013)]. Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)]. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes that are essential for maintaining intracellular levels of reactive oxygen species. Inhibition of these enzymes leads to cellular oxidative stress and intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Fan et al. (Cell Death Dis 5:e1191, 2014), Fiskus et al. (Cancer Res 74:2520-2532, 2014), Marzano et al. (Free Radic Biol Med 42:872-881, 2007)]. Drugs such as auranofin that have already been approved for human use [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)] can be brought into clinical use for other diseases relatively quickly and for a fraction of the cost of new drugs. Language eng DOI 10.1007/s40268-015-0083-y Field of Research 111502 Clinical Pharmacology and Therapeutics Socio Economic Objective 920204 Evaluation of Health Outcomes HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2015, Springer Free to Read? Yes Persistent URL http://hdl.handle.net/10536/DRO/DU:30072102 Document type: Journal Article Collections: Faculty of Health School of Medicine Open Access Collection Related Links Link Description Link to full-text (open access)   Connect to published version Go to link with your DU access privileges   Author URL Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au. Versions Version Filter Type Thu, 09 Apr 2015, 10:45:23 EST Fri, 10 Apr 2015, 05:01:07 EST Tue, 14 Apr 2015, 08:11:00 EST Thu, 06 Aug 2015, 06:09:12 EST Thu, 13 Aug 2015, 14:18:18 EST Thu, 13 Aug 2015, 14:19:50 EST Fri, 14 Aug 2015, 08:07:15 EST Fri, 21 Apr 2017, 07:07:20 EST Sun, 10 Nov 2019, 00:39:19 EST Sat, 05 Sep 2020, 02:39:26 EST Filtered Full Citation counts:   Cited 177 times in TR Web of Science Cited 185 times in Scopus Search Google Scholar Access Statistics: 130 Abstract Views, 2 File Downloads  -  Detailed Statistics Created: Thu, 09 Apr 2015, 10:45:23 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.